Maruyama Y, Anami K, Terasawa M, Goto K, Imayoshi T, Kadobe Y, Mizushima Y
Arzneimittelforschung. 1981;31(7):1111-8.
Anti-inflammatory activity of 2-[p-(2-imidazo[1,2-a]pyridyl) phenyl]propionic acid (Y-9213, miroprofen) was studied on various experimental models. Miroprofen was found to be as active as indomethacin against the exudative inflammation such as pleuritis in rats induced by Evans blue-carrageenin and the peritonitis in mice induced by acetic acid, and against the local Shwartzman reaction in rabbits. Miroprofen also inhibited the formation of edema induced by carrageenin or kaolin in rats' paws at lower doses. Against the proliferation of connective tissues, miroprofen showed the inhibitory action at higher doses. The ulcerogenic activity of miroprofen in rats was less potent than that of indomethacin, and as active as that of phenylbutazone. These findings indicate that miroprofen may be more effective in suppressing pain responses and acute inflammation accompanied with increased vascular permeability.
研究了2-[对-(2-咪唑并[1,2-a]吡啶基)苯基]丙酸（Y-9213，米洛芬）在各种实验模型上的抗炎活性。发现米洛芬在对抗诸如伊文思蓝-角叉菜胶诱导的大鼠胸膜炎和乙酸诱导的小鼠腹膜炎等渗出性炎症以及家兔局部施瓦茨曼反应方面与吲哚美辛活性相当。米洛芬在较低剂量时也能抑制角叉菜胶或高岭土诱导的大鼠爪部水肿形成。在对抗结缔组织增殖方面，米洛芬在较高剂量时表现出抑制作用。米洛芬在大鼠中的致溃疡活性比吲哚美辛弱，与保泰松相当。这些发现表明米洛芬在抑制疼痛反应和伴有血管通透性增加的急性炎症方面可能更有效。
